[Previous infection with Chlamydia pneumoniae and long-term prognosis in patients with acute coronary syndrome with non-ST segment elevation]. / Infección previa por Chlamydia pneumoniae y pronóstico a largo plazo en pacientes con síndrome coronario agudo sin elevación del segmento ST.

BACKGROUND AND OBJECTIVE: Contradictory data exists from case-control studies and in patients with stable coronary artery disease on the association of prior exposure to Chlamydia pneumoniae and cardiovascular events. We underwent a prospective study to investigate the prognostic value of C. pneumoniae seropositivity in patients with acute coronary syndromes. PATIENTS AND METHOD: In a prospective cohort of 259 consecutive patients (194 men and 65 women), mean age 65 (10 years) with non-ST elevation acute coronary syndromes, we measured serum levels of IgG antibodies directed against C. pneumoniae. RESULTS: After a mean follow-up of 28 (25, 29) months, the incidence of cardiovascular death or myocardial infarction was of 15% in seropositive patients versus 13% in seronegatives at IgG titers (1:64 (p=0.58); of 14% versus 14% at IgG titers > or = 1:128 (p=0.96); and of 14% versus 15% at IgG titers (1:256 (p=0.82). The relative risks (RR, 95% CI) of these major cardiac events adjusted for possible confounding factors were 1.11 (0.52-2.40); 1.01 (0.52-1.96); and 0.94 (0.48-1.87) respectively. CONCLUSIONS: Chlamydia pneumoniae IgG seropositivity is not associated with a higher incidence of death or myocardial infarction in patients with non-ST segment elevation acute coronary syndromes.

Infección previa por Chlamydia pneumoniae y pronóstico a largo plazo en pacientes con síndrome coronario agudo sin elevación del segmento ST / Previous infection with Chlamydia pneumoniae and long-term prognosis in patients acute coronary syndrome and with non-ST segment elevation

Fundamento y objetivo: Existen datos contradictorios procedentes de estudios de casos y controles y en pacientes con enfermedad coronaria estable sobre la asociación entre exposición previa a Chlamydia pneumoniae y accidentes cardiovasculares. Realizamos un estudio prospectivo con el fin de investigar el valor pronóstico de la seropositividad anti-C. pneumoniae en pacientes con síndrome coronario agudo. Pacientes y método: Se determinó la concentración en suero de anticuerpos inmunoglobulina (Ig) G anti-C. pneumoniae en una cohorte de 259 pacientes consecutivos con síndrome coronario agudo sin elevación del segmento ST (194 varones y 65 mujeres), con una edad media ( desviación estándar) de 65 (10) años. Resultados: Tras un seguimiento medio de 28 (percentiles 25, 75: 25, 29) meses, la incidencia de mortalidad cardiovascular o infarto de miocardio fue del 15% en los pacientes seropositivos frente al 13% en los seronegativos para concentraciones de IgG mayores o iguales a 1:64 (p = 0,58); del 14% frente al 14% para IgG mayor o igual a 1:128 (p = 0,96); y del 14% frente al 15% para IgG mayor o igual a 1:256 (p = 0,82). El riesgo relativo (intervalo de confianza del 95%) ajustado por posibles factores de confusión fue de 1,11 (0,52-2,40), 1,01 (0,52-1,96) y 0,94 (0,48-1,87), respectivamente. Conclusiones: La existencia de seropositividad IgG para C. pneumoniae no se asocia con una mayor incidencia de muerte o infarto en pacientes con síndrome coronario agudo sin elevación del ST

Background and objective: Contradictory data exists from case-control studies and in patients with stable coronary artery disease on the association of prior exposure to Chlamydia pneumoniae and cardiovascular events. We underwent a prospective study to investigate the prognostic value of C. pneumoniae seropositivity in patients with acute coronary syndromes. Patients and method: In a prospective cohort of 259 consecutive patients (194 men and 65 women), mean age 65 (10 years) with non-ST elevation acute coronary syndromes, we measured serum levels of IgG antibodies directed against C. pneumoniae. Results: After a mean follow-up of 28 (25, 29) months, the incidence of cardiovascular death or myocardial infarction was of 15% in seropositive patients versus 13% in seronegatives at IgG titers (1:64 (p=0.58); of 14% versus 14% at IgG titers >= 1:128 (p=0.96); and of 14% versus 15% at IgG titers (1:256 (p=0.82). The relative risks (RR, 95% CI) of these major cardiac events adjusted for posible confounding factors were 1.11 (0.52-2.40); 1.01 (0.52-1.96); and 0.94 (0.48-1.87) respectively. Conclusions: Chlamydia pneumoniae IgG seropositivity is not associated with a higher incidence of death or myocardial infarction in patients with non-ST segment elevation acute coronary syndromes